CUTR - Cutera, Inc.
NASDAQ
->
Healthcare
->
Medical Devices
Brisbane,
United States
Type: Equity
CUTR price evolution
CUTR
| (in millions $) | 31 Jan 2024 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $180.22 | $181.35 | $167.53 | |
| Short term investments | $41.95 | $100.82 | ||
| Net receivables | $43.37 | $49.83 | $53.08 | $52.14 |
| Inventory | $61.73 | $61.85 | $68.67 | $71.82 |
| Total current assets | $268.33 | $311.31 | $369.95 | $418.46 |
| Long term investments | ||||
| Property, plant & equipment | $47.33 | $80.61 | $76.88 | $65.08 |
| Goodwill & intangible assets | $1.34 | $1.34 | $1.34 | |
| Total noncurrent assets | $95.33 | $93.88 | $81.33 | |
| Total investments | $41.95 | $100.82 | ||
| Total assets | $355.17 | $406.63 | $463.83 | $499.8 |
| Current liabilities | ||||
| Accounts payable | $19.83 | $31.37 | $34.24 | $35.17 |
| Deferred revenue | $13.11 | $14.15 | $13.89 | |
| Short long term debt | $2.51 | $2.6 | $2.72 | |
| Total current liabilities | $84.62 | $92.41 | $103.06 | $108.79 |
| Long term debt | $418.69 | $427.6 | $427.64 | $427.66 |
| Total noncurrent liabilities | $430.31 | $429.9 | $430.02 | |
| Total debt | $430.11 | $430.24 | $430.38 | |
| Total liabilities | $515 | $522.72 | $532.97 | $538.81 |
| Shareholders' equity | ||||
| Retained earnings | -$291.34 | -$246.11 | -$197.17 | -$165.53 |
| Other shareholder equity | $0 | -$0.01 | ||
| Total shareholder equity | -$116.08 | -$69.14 | -$39.01 | |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $146.62 | $164.86 | $47.05 | |
| Short term investments | $171.39 | |||
| Net receivables | $43.37 | $45.56 | $31.45 | $21.96 |
| Inventory | $61.73 | $63.63 | $39.5 | $28.51 |
| Total current assets | $268.33 | $451.24 | $249.66 | $106.3 |
| Long term investments | ||||
| Property, plant & equipment | $47.33 | $53.2 | $17.65 | $19.38 |
| Goodwill & intangible assets | $1.34 | $1.34 | $1.34 | |
| Total noncurrent assets | $69.75 | $30.63 | $26.44 | |
| Total investments | $171.39 | |||
| Total assets | $355.17 | $520.99 | $280.29 | $132.73 |
| Current liabilities | ||||
| Accounts payable | $19.83 | $33.74 | $7.89 | $6.68 |
| Deferred revenue | $13.5 | $10.82 | $11.24 | |
| Short long term debt | $2.81 | $2.42 | $5.89 | |
| Total current liabilities | $84.62 | $105.84 | $73.9 | $54.36 |
| Long term debt | $418.69 | $416.46 | $147.73 | $19.5 |
| Total noncurrent liabilities | $430.33 | $149.82 | $21.5 | |
| Total debt | $430.62 | $150.15 | $25.39 | |
| Total liabilities | $515 | $536.17 | $223.72 | $75.85 |
| Shareholders' equity | ||||
| Retained earnings | -$291.34 | -$140.51 | -$58.17 | -$60.23 |
| Other shareholder equity | -$0.09 | |||
| Total shareholder equity | -$15.18 | $56.57 | $56.88 | |
| (in millions $) | 31 Jan 2024 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $49.54 | $46.48 | $61.22 | $54.99 |
| Cost of revenue | $40.02 | $33.16 | $30.07 | |
| Gross Profit | $6.24 | $6.46 | $28.05 | $24.93 |
| Operating activities | ||||
| Research & development | $4.59 | $5.78 | $6.47 | |
| Selling, general & administrative | $42.81 | $51.8 | $42.03 | |
| Total operating expenses | $50.56 | $47.4 | $57.58 | $48.5 |
| Operating income | -$40.95 | -$29.53 | -$23.57 | |
| Income from continuing operations | ||||
| EBIT | -$41.17 | -$28.36 | -$21.8 | |
| Income tax expense | $0.77 | $0.17 | $0.33 | $0.27 |
| Interest expense | -$1.18 | $2.94 | $2.96 | $2.94 |
| Net income | ||||
| Net income | -$45.23 | -$44.27 | -$31.64 | -$25.02 |
| Income (for common shares) | -$44.27 | -$31.64 | -$25.02 | |
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $212.37 | $252.4 | $231.27 | $147.68 |
| Cost of revenue | $112.57 | $98.17 | $71.91 | |
| Gross Profit | $60.41 | $139.83 | $133.1 | $75.77 |
| Operating activities | ||||
| Research & development | $25.16 | $21.57 | $14.32 | |
| Selling, general & administrative | $152.86 | $109.71 | $84.28 | |
| Total operating expenses | $203.44 | $178.02 | $131.28 | $98.6 |
| Operating income | -$38.19 | $1.83 | -$22.83 | |
| Income from continuing operations | ||||
| EBIT | -$75.04 | $5.9 | -$23.41 | |
| Income tax expense | $1.53 | $1.64 | $1.32 | $0.47 |
| Interest expense | -$3.07 | $5.66 | $2.51 | |
| Net income | ||||
| Net income | -$150.83 | -$82.34 | $2.06 | -$23.88 |
| Income (for common shares) | -$82.34 | $2.06 | -$23.88 | |
| (in millions $) | 31 Jan 2024 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$44.27 | -$31.64 | -$25.02 | |
| Operating activities | ||||
| Depreciation | $1.99 | $1.83 | $1.41 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $1.62 | $1.55 | $3.39 | |
| Total cash flows from operations | -$36.88 | -$31.27 | -$37.06 | |
| Investing activities | ||||
| Capital expenditures | -$5.53 | -$14.76 | -$11.15 | |
| Investments | $41.04 | $60 | $71.53 | |
| Total cash flows from investing | $137.19 | $35.51 | $45.24 | $60.38 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.47 | $0.75 | $0.11 | |
| Net borrowings | -$0.15 | -$0.11 | -$0.12 | |
| Total cash flows from financing | -$2.57 | $0.23 | -$0.15 | -$2.41 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$3.01 | -$1.14 | $13.83 | $20.9 |
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$82.34 | $2.06 | -$23.88 | |
| Operating activities | ||||
| Depreciation | $2.62 | $1.34 | $1.39 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $14.4 | $13.17 | $10.11 | |
| Total cash flows from operations | -$67 | $1.24 | -$16.93 | |
| Investing activities | ||||
| Capital expenditures | -$22.7 | -$0.94 | -$1.25 | |
| Investments | -$171.48 | $7.64 | ||
| Total cash flows from investing | $137.19 | -$194.18 | -$0.94 | $6.39 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $2.72 | $2.77 | $30.38 | |
| Net borrowings | $302.5 | $133.07 | $6.63 | |
| Total cash flows from financing | -$2.57 | $242.94 | $117.53 | $31.28 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$3.01 | -$18.24 | $117.82 | $20.73 |
News
Fundamentals
| Market cap | $38.72M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 19.96M |
| Revenue | $212.23M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$146.16M |
| Revenue Q/Q | -26.45% |
| Revenue Y/Y | N/A |
| P/E ratio | -0.26 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 0.18 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$7.32 |
|---|---|
| ROA | -33.88% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 3.17 |
| Quick ratio | 2.44 |